drugset / Trial / NCT06035406

A Trial of SP2086 With Hepatic Insufficiency

NCT06035406

Phase 1 Unknown 24 enrolled Jiangsu HengRui Medicine Co., Ltd.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study used a single-dose, open design to compare the pharmacokinetics of subjects with mild and moderate liver impairment and subjects with normal liver function.

Timeline

Start
2023-09
Primary completion
2023-12
Completion
2023-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Retagliptin Small molecule 100 mg

Indications